Sources describe Mr. Manthei as “brilliant, highly strategic and consistently on schedule with work.” He also has “a talent for understanding the nuances of engaging the FDA or policy makers in a constructive rather than confrontational way” and an “almost encyclopedic knowledge of FDA regulations.”

Chambers USA 2010 - 2017

John R. Manthei

Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
 
 

John R. Manthei is a partner in the Washington, D.C. office of Latham & Watkins and serves as global Co-chair and Washington, D.C. Chair of the Healthcare & Life Sciences Practice. His practice focuses on regulatory matters involving the Food and Drug Administration (FDA) for the medical device, pharmaceutical, biotechnology, and dietary supplement industries.

Mr. Manthei’s practice includes assisting clients with all aspects of the FDA-regulated product life cycle, including, among others:

  • Pre-market development
  • FDA product submissions

  • Development of market exclusivity strategies

  • Drafting and negotiation of both US and international clinical trial agreements

  • FDA and Federal Trade Commission (FTC) regulation of marketing and promotion of products

  • Quality System Regulation and Good Manufacturing Practice requirements (including assisting in third-party audits and drafting SOPs)

  • FDA inspections

  • Recalls

  • FDA and Drug Enforcement Administration (DEA) export and import requirements

  • Civil and criminal compliance and enforcement

Mr. Manthei has also been involved extensively in Administrative Procedures Act litigation, including successfully challenging the Agency in Sotttera/NJOY v. FDA, Commonwealth v. FDA and Pacira v. FDA, as well as successfully intervening to defend FDA actions on behalf of clients in Teva v. FDA, and Weyth Pharmaceuticals v. FDA.

Prior to joining Latham, Mr. Manthei served as Majority Counsel for the US House of Representatives’ Committee on Energy and Commerce (1998-2000). In this capacity, he counseled the Full Commerce Committee, the Health and Environment, and Oversight and Investigations Subcommittee Chairmen, as well as the House Leadership on matters relating to the FDA and legislation concerning the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and the Controlled Substances Act. Since 2000, Mr. Manthei has represented the pharmaceutical, biotechnology, and medical device industries as counsel in nearly every major FDA legislative initiative. He has also testified before Congress on several occasions involving FDA and DEA regulatory and enforcement matters.

Mr. Manthei serves as outside FDA counsel to the Medical Device Manufacturers Association (MDMA) and as a member of the Food & Drug Law Institute (FDLI) Advisory Committee for Medical Devices. He also previously served as a member of FDLI’s Advisory Committee for Drugs and Biologics. Mr. Manthei has been recognized for his life sciences practice in numerous publications, most recently as a “Life Sciences MVP” by Law360 (2016). He has been repeatedly named a leading life sciences lawyer by Chambers USA (2010 – 2017) and The Legal 500 US (2012 – 2017), which notes that he has “an encyclopedic knowledge of the FDA regulations” and “takes the time to become an expert on the product.” In addition, he has been recognized as one of “Washington's Best Lawyers” by Washingtonian magazine (2013), a “Life Sciences Industry Star” by Euromoney and LMG Life Sciences (2012 – 2016), one of the “Top 40 Lawyers Under 40” by Washingtonian magazine (2006), and in Who’s Who in America, Who’s Who in American Law, Who’s Who International, and Who’s Who Legal: Lifesciences.

Mr. Manthei has authored numerous articles and has been a featured speaker and lecturer on FDA regulatory and enforcement matters at events sponsored by the Pharmaceutical Research and Manufacturers Association (PhRMA), the Biotechnology Industry Organization (BIO), AdvaMed, MDMA, BioCom, BayBio, the Food and Drug Law Institute (FDLI), the American Health Lawyers Association (AHLA), GMA, Harvard University, Stanford University and MIT, among others. Mr. Manthei also serves on the editorial boards of BNA’s Medical Device Law & Industry Report and LifeSciencesLaw 360.

In addition, Mr. Manthei has been quoted in CBS News, Washington Post, CNN, USA Today, CNBC, Boston Globe, San Francisco Chronicle, Forbes, Business Week, and other leading national and international business journals on FDA regulatory, enforcement, and policy matters.

Some of Mr. Manthei’s recent publications include:

  • “FCA Reauthorization Act Aims to Speed Product Reviews Through User Fee Funding,” Latham & Watkins Client Alert (August 2017) 
  • “FDA Works to Increase Competition Under Commissioner's Drug Competition Action Plan,” Latham & Watkins Client Alert (June 2017)
  • The Regulation of Follow-On Biologics: FDA Authority and Implementation,” FDLI Publications (January 2014)
  • “Off Label Promotion: New FDA Standards and Guidance,” Medical Devices Law & Industry Report, Bloomberg News (April 2014)
  • “The Food and Drug Administration Safety and Innovation Act of 2012: Assessing the Impact on the Pharmaceutical and Biotechnology Industries,” BNA’s Pharmaceutical Law and Industry Report (August 2012)
  • “The Food and Drug Administration Safety and Innovation Act of 2012: Assessing the Impact on the Medical Device Industry,” BNA’s Medical Device Law and Industry Report (August 2012)
  • “Maintaining Eligibility for FDA Small Business Waivers Is Not So Simple: Practical Considerations for Structuring Investments in Emerging Pharmaceutical Companies in Light of SBA’s Restrictive Policies,” FDLI Update (September/October 2011)
  • “Medical Device Reform is (Almost) Here: FDA Announces Action Items for Improving the Agency’s 510(k) Premarket Clearance Process,” Medical Devices Law & Industry Report (March 2011)
  • “A Brave New World: The U.S. Food and Drug Administration's Newfound Authority for Regulation of Follow-on Biologics,” Bloomberg Law Reports (May 2010) 
  • “What to Think About When Considering an Overseas Clinical Trial Program,” BioWorld Perspectives (March 2009) 
  • “Exclusivity Strategies in the United States and European Union,” FDLI Update (May 2009)
    • Blood pressure monitor
    • May 2014
      Presentation looks at how biotechnology-related inventions may or may not qualify as patentable subject matter, the scope and boundaries of the FDA “safe harbor” exception to patent infringement, and the future of “biosimilar” drug approval and regulation under the biologics Price Competition and Innovation Act.
      share view
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.